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Background. Choroid plexus tumors are intraventricular neoplasms derived from the choroid plexus epithelium. A better knowl-
edge of molecular factors involved in choroid plexus tumor biology may aid in identifying patients at risk for recurrence.
Methods. Methylation profiles were examined in 29 choroid plexus papillomas (CPPs, WHO grade I), 32 atypical choroid plexus
papillomas (aCPPs, WHO grade II), and 31 choroid plexus carcinomas (CPCs, WHO grade III) by Illumina Infinium HumanMethy-
lation450 Bead Chip Array.
Results. Unsupervised hierarchical clustering identified 3 subgroups: methylation cluster 1 (pediatric CPP and aCPP of mainly
supratentorial location), methylation cluster 2 (adult CPP and aCPP of mainly infratentorial location), and methylation cluster
3 (pediatric CPP, aCPP, and CPC of supratentorial location). In methylation cluster 3, progression-free survival (PFS) accounted
for a mean of 72 months (CI, 55-89 mo), whereas only 1 of 42 tumors of methylation clusters 1 and 2 progressed (P, .001).
On stratification of outcome data according to WHO grade, all CPCs clustered within cluster 3 and were associated with shorter
overall survival (mean, 105 mo [CI, 81-128 mo]) and PFS (mean, 55 mo [CI, 36-73 mo]). The aCPP of methylation cluster 3 also
progressed frequently (mean, 69 mo [CI, 44-93 mo]), whereas no tumor progression was observed in aCPP of methylation clusters
1 and 2 (P, .05). Only 1 of 29 CPPs recurred.
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Conclusions. Methylation profiling of choroid plexus tumors reveals 3 distinct subgroups (ie, pediatric low-risk choroid plexus tu-
mors [cluster 1], adult low-risk choroid plexus tumors [cluster 2], and pediatric high-risk choroid plexus tumors [cluster 3]) and
may provide useful prognostic information in addition to histopathology.
Keywords: atypical choroid plexus papilloma, choroid plexus carcinoma, copy-number alterations, epigenetics, prognosis.
Choroid plexus tumors are rare intraventricular neoplasms de-
rived from the choroid plexus epithelium and represent 0.2% of
all central nervous system neoplasms and 10%–20% of brain
tumors arising during the first year of life.1,2 According to the
World Health Organization (WHO) classification, choroid plexus
tumors can be divided into 3 entities based on histopathologi-
cal features. Choroid plexus papilloma (CPP, WHO grade I)
closely resembles normal choroid plexus tissue. The defining
feature of atypical choroid plexus papilloma (aCPP, WHO
grade II) is the presence of increased mitotic activity (≥2 mito-
ses/10 high-power fields), while choroid plexus carcinoma
(WHO grade III) is characterized by frank signs of malignancy
including brisk mitotic activity, nuclear pleomorphism, high cel-
lularity, blurring of the papillary growth pattern, and necrosis.3
In very young children, CPP and aCPP share molecular signa-
tures and a comparable excellent outcome.4,5 In contrast, aCPP
is associated with recurrence in older children (≥3 y) and
adults.6,7 Underlying biological factors explaining these age-
dependent prognostic differences in aCPP remain uncertain. In
recent years, high-resolution molecular profiling led to the iden-
tification of distinct molecular subgroups in a variety of tumor
entities.8 –10 High-density DNA methylation arrays allow robust
molecular subgrouping and copy number profiling from small
amounts of archival formalin-fixed paraffin-embedded (FFPE)
material.11 Recently, methylation profiling has been reported
to segregate CPC from CPP and aCPP.4 Interestingly, methylation
profiles of some CPPs and aCPPs in this series also clustered with
CPCs, raising the possibility that methylation profiling could be
used to identify patients at risk of tumor recurrence.
We aimed to characterize methylation profiles and clinical
and histopathological features in a larger series of choroid plex-
us tumors across all age groups. Here we show that methyla-
tion profiling of choroid plexus tumors reveals 3 distinct
molecular subgroups, which may aid in identifying patients at
risk of recurrence.
Materials and Methods
Samples and Patients
FFPE samples of 92 choroid plexus tumors were collected from
the archives of the Institutes of Neuropathology in Mu¨nster,
Heidelberg, Bremen, Du¨sseldorf, Essen, Frankfurt, Tu¨bingen,
and Wu¨rzburg as well as institutions that had previously sub-
mitted cases for reference in context of the CPT-SIOP trials.
Two cases were retrieved from the Children’s Cancer and Leu-
kemia Group Tissue Bank, Leicester, UK. Of these tumors, 19
had already been included in a previous series examining copy-
number alterations using high-resolution arrays.12 The histopa-
thology of all samples was reviewed according to 2007 WHO
criteria. Follow-up information could be retrieved from the
CPT-SIOP registry and treating physicians for 77 cases (84%).
Three non-neoplastic choroid plexus samples obtained from
neuropathologically normal autopsy brains served as controls.
Investigations were approved by the Mu¨nster ethics committee
(2007-420-f-S).
Immunohistochemistry
Staining for p53 was performed using a mouse monoclonal
antibody (BP53–12; 1:100; citrate buffer pH 6.1 for antigen
retrieval; Zytomed). The streptavidin-biotin method was used
on an automated staining system (TechMate, DAKO). Expression
of p53 was evaluated semiquantitatively by scoring the percent-
age of stained nuclei. Strong nuclear staining in .10% of tumor
cells was considered positive.
450k Methylation Array
Genomic DNA was isolated from FFPE material using the Max-
well LEV FFPE Tissue DNA Purification Kit (Promega). DNA was
subjected to quality analysis using the Infinium HD FFPE QC
assay protocol (Illumina). Tumor samples were then subjected
to bisulfite conversion using the EZ DNA Methylation-Gold-Kit
(Zymo Research), followed by the Infinium HD FFPE restore pro-
tocol. Samples were analyzed using the Illumina Infinium
HumanMethylation450 Bead Chip according to the manufac-
turer’s instructions at the Core Facility Genomics of the Medical
Faculty Mu¨nster or the German Cancer Research Center (DKFZ)
Genomics and Proteomics Core Facility. The following criteria
were applied to filter the data: removal of probes targeting
sex chromosomes, removal of probes containing a single nucle-
otide polymorphism (dbSNP132 Common) within 5 base pairs
of and including the targeted CpG-site (n¼ 24 536) and probes
not mapping uniquely to the human reference genome (hg19)
allowing for one mismatch (n¼ 9993). In total, 438 370 probes
were kept for analysis.
To cluster samples and determine an optimal number of stable
clusters, unsupervised consensus clustering13 was applied. Cluster-
ing was performed using the beta values of the 10 000 most
variable methylated probes as measured by median absolute devi-
ation. Within each of the 1000 resampling iterations of the consen-
sus clustering, a hierarchical clustering using ward linkage as
agglomeration method and Euclidean distance as distance
measure was applied. A stable clustering for K¼3 clusters was de-
termined by visually inspecting the resulting consensus matrices
and delta-K criteria. To reorder the 10 000 most variable probes
for the heat map visualization, probes were clustered by agglom-
erative hierarchical clustering using the Euclidean distance as dis-
tance measure and average linkage as agglomeration method.
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Copy-number Analysis
Copy-number profiles were derived from intensity measures of
the methylation probes as recently described10 using the “con-
umee” R package available through BioConductor (http://
bioconductor.org/packages/release/bioc/html/conumee.html).
A total of 72 tumors fulfilled the quality criteria for copy-
number analysis.
Statistical Analysis
Patient characteristics were summarized using median and
interquartile range (IQR) for continuous variables as well as fre-
quency and percentage for categorical variables. Overall sur-
vival (OS) time was defined as the time from the date of
diagnosis to the date of death. Progression-free survival (PFS)
time was defined as the time from the date of diagnosis to
the date of death or relapse, whichever occurred first. Continu-
ous and categorical variables were compared using the
Mann-Whitney U test and the chi-square test, respectively.
For the comparison of genetic alterations, the chi-square test
with Bonferroni correction for multiple comparisons was ap-
plied. Survival analysis was performed using Kaplan-Meier esti-
mation for survival curves and the log-rank test using IBM SPSS
22 software (release 22.0). In order to adjust for confounders
among co-factors, a multivariate Cox proportional hazards
model was fit. Forward stepwise model selection was per-
formed by the Wald approach with the saturated model includ-
ing WHO grade, age, location, copy-number alterations, and
p53 status as co-factors. For all analyses, P, .05 was consid-
ered to be significant.
Results
The 92 choroid plexus tumors comprised 29 CPPs (31%), 32
aCPPs (35%), and 31 CPCs (34%). As shown in Table 1, the me-
dian age of the 54 male and 38 female patients was 4 years
(IQR, 1–16 y). Fifty-nine tumors (64%) were located supraten-
torially (ie, in the lateral or the third ventricle), whereas
27 tumors [29%] were of infratentorial location in the vicinity
of the fourth ventricle. Data on tumor location were not avail-
able for 6 tumors (7%). Overexpression of p53 protein was ob-
served in 9 of 30 CPCs (37%) and 1 of 25 (4%) aCPPs that could
be examined. For further details on patient characteristics and
treatment, see Supplementary material, Table S1.
Unsupervised hierarchical clustering of DNA methylation
patterns of the 92 tumors resulted in 3 clusters (Fig. 1). Tumors
of methylation cluster 1 comprised 8 CPPs (44%) and 10 aCPPs
(56%) characterized by young age [median age, 1 y [IQR, 0–6 y)]
and mainly supratentorial location (72%). As shown in Fig. 1B,
frequent copy-number alterations observed in methylation
cluster 1 included gains of chromosomes 12 (62%), 9p (62%),
and 11 (54%). In contrast, tumors of methylation cluster 2 (16
CPPs [67%] and 8 aCPPs [33%]) were characterized by adult
age (median age, 38 y [IQR, 25–52 y]) and mainly infratentorial
location (88%). Frequent copy-number alterations observed in
methylation cluster 2 included gains of chromosomes 5 (82%),
7 (77%), and 9 (72%) as well as losses of chromosome 21q
(64%). Tumors of methylation cluster 3 comprised CPCs (31
CPCs (62%) but also 14 aCPPs (28%) and 5 CPPs (10%). They
were characterized by young age (median age, 2 y [IQR, 1–6
y]) and supratentorial location (88%). Recurrent copy-number
alterations observed in methylation cluster 3 included chromo-
somal losses such as 6q (73%), 6p, 22 (70%), 11p, 1, 6, and 19q
(65%). Gains affecting chromosome 1p32–35.3, for which a
role in the oncogenesis of CPC has been recently suggested,14
were present in 10 cases (20%) of methylation cluster 3 (8 CPCs
and 2 aCPPs) but not in the other clusters (chi-square P¼ .02).
As shown in Supplementary material, Table S2, and summa-
rized in Supplementary material, Figure S1, a number of
genes was differentially methylated between clusters. Interest-
ingly, MGMT was not among the differentially methylated
genes but was unmethylated in all choroid plexus tumors
examined.
The majority of CPPs and aCPPs were encountered within
methylation cluster 1 and methylation cluster 2. Both of
these clusters differed significantly by age and tumor location
(P, .001). Both methylation clusters also differed on the
Table 1. Patient characteristics
All (N¼ 92) Cluster 1 (N¼ 18) Cluster 2 (N¼ 24) Cluster 3 (N¼ 50)
Sex (male/female) 54/38 11/7 11/13 32/18
Diagnosis
CPP 29 (31%) 8 (44%) 16 (67%) 5 (10%)
aCPP 32 (35%) 10 (56%) 8 (33%) 14 (28%)
CPC 31 (34%) 0 (0%) 0 (0%) 31 (62%)
Age (y) (median, IQR) 4 (1–16) 1 (0–6) 38 (25–52) 2 (1–6)
Location
Supratentorial 59 (64%) 13 (72%) 2 (8%) 44 (88%)
Infratentorial 27 (29%) 5 (28%) 21 (88%) 1 (2%)
Unknown 6 (7%) 0 (0%) 1 (4%) 5 (10%)
Positive p53 status (nuclear accumulation of p53
protein in .10% of tumor cells)
10/75 (13%) 0/13 (0%) 0/16 (0%) 10/46 (22%)
Abbreviations: aCPP, atypical choroid plexus papilloma; CPC, atypical choroid plexus papilloma; CPP, choroid plexus papilloma; IQR, interquartile
range.
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Fig. 1. Methylation profiling of choroid plexus tumors. (A) Heat map of hierarchical clustering of methylation profiles as well as tumor location,
neuropathological diagnosis, progression status, p53 status, and patient age. Note that choroid plexus tumors can be divided into 3 clusters:
methylation cluster 1 (young age and mainly supratentorial location), methylation cluster 2 (adult age and mainly infratentorial location), and
methylation cluster 3 (young age and supratentorial location). Legend: aCPP, atypical choroid plexus papilloma; CPP, choroid plexus papilloma; CPC,
choroid plexus carcinoma; NA, not available. (B) For each sample (N¼ 72) copy-number alterations (CNAs) are shown as indicated (green for
chromosomal gain and red for chromosomal loss). (C) Kaplan Meier analysis showing that methylation cluster 3 is associated with shorter
overall survival and progression-free survival as compared with methylation clusters 1 and 2. Log-rank test P, .05 and P, .001, respectively.
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Fig. 2. Methylation profiling identifies molecular high-risk and low-risk clusters. Kaplan-Meier estimates of progression-free survival according to
methylation clusters, examined (A) in choroid plexus carcinomas (WHO grade III, N¼ 26), (B) in atypical choroid plexus papillomas (WHO grade II,
N¼ 27), and (C) choroid plexus papillomas (WHO grade I, N¼ 23). Note significant prognostic role of methylation clustering in atypical choroid
plexus papillomas (log-rank test P, .05).
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genetic level, with gains of chromosome 5 and losses of chromo-
some 21q being more frequently encountered in methylation
cluster 2 (P¼ .0001 and P¼ .02, respectively). Irrespective of
these differences, outcome in methylation cluster 1 and meth-
ylation cluster 2 was favorable: only one patient experienced
tumor progression, and no patient succumbed to disease (me-
dian follow-up, 78 mo). In contrast, the prognosis of patients in
methylation cluster 3 was worse. In this cluster, which con-
tained all CPCs and all p53-positive tumors examined, a total
of 8 tumor-related deaths occurred, whereas none of the
patients of methylation cluster 1 and methylation cluster 2 suc-
cumbed to disease (Fig. 1C, log-rank test P, .05). On Kaplan-
Meier analysis (Fig. 1D), estimated PFS accounted for a mean
of only 72 months (CI, 55-89 mo) while only 1 of 42 tumors
(2%) in methylation clusters 1 and 2 recurred (log-rank test
P, .001). On multivariate analysis taking into account WHO
grade, age, location, copy-number alterations, and p53 status
as co-factors, however, WHO grade (but not methylation clus-
tering) was the only independent predictor of OS, whereas WHO
grade and p53 status remained the only predictors of PFS.
Next, the prognostic role of methylation clustering was
examined according to WHO grade. As shown in Fig. 2A, all
CPCs (WHO grade III) clustered in cluster 3 and were associated
with decreased OS (mean, 105 mo [CI, 81-128 mo]) and PFS
(mean, 55 mo [CI, 36-73 mo]). Importantly, however, all recur-
rences observed in aCPPs (WHO grade II) also occurred in this
cluster (cluster 3; mean PFS, 69 mo [CI, 44-93 mo]), while none
of the aCPPs of the low-risk clusters (cluster 1 and cluster 2)
progressed (Fig. 2B, P, .05). Only one CPP (WHO grade I) of
the whole cohort recurred (cluster 2, Fig. 2C). Taken together,
these data demonstrate that methylation profiling might
be especially useful for identifying aCPPs at increased risk of
recurrence (ie, those aCPPs clustering within methylation
cluster 3).
Discussion
Using methylation profiling of choroid plexus tumors across all
age ranges and anatomical locations, 3 molecular clusters
were identified. These clusters are of clinical importance: meth-
ylation cluster 1 (young age and mainly supratentorial location)
and methylation cluster 2 (adult age and mainly infratentorial
location) are characterized by low risk of tumor progression,
while methylation cluster 3 (young age and supratentorial lo-
cation) contains choroid plexus tumors with a higher risk of
progression.
Two recent studies highlighted molecular similarities of CPP
and aCPP in young children based on copy-number profiling,
DNA methylation, and gene expression signatures.4,5 Our data
confirm these findings, showing that some pediatric aCPPs with
favorable prognosis indeed cluster together with CPPs (methyl-
ation cluster 1). However, by taking advantage of a larger
cohort of patients, our study also demonstrated that a signifi-
cant proportion of pediatric CPPs and aCPPs cluster together
with CPCs (methylation cluster 3) and are associated with
a higher risk of tumor progression. Even though the possibility
of sampling bias cannot be entirely excluded, none of these
tumors met histopathological criteria for CPC on central review.
Our results show that methylation profiling can successfully
supplement the histopathological examination for the identifi-
cation of patients at risk of tumor progression. This holds
especially true for patients harboring aCPPs, which may cluster
with methylation clusters 1 and 2 (low risk of progression) or
methylation cluster 3 (high risk of progression). Since increased
mitotic activity (ie, the defining histopathological feature of
aCPP) has recently been shown to be of limited prognostic
relevance,7 this finding is of clinical importance. In the present
series, which represents the largest study on epigenetic patterns
in choroid plexus tumors reported to date, consensus clustering
resulted in 3 stable and clinically relevant subgroups. Neverthe-
less, examination of even larger cohorts might potentially reveal
additional subgroups (eg, within methylation cluster 3). Methyl-
ation profiling is a robust and reliable high throughput method
suitable for use on FFPE tissues and will be easy to implement
into the work flow of international trials and registries.
The observation that adult choroid plexus tumors of infra-
tentorial location also show unique methylation profiles is
novel and further supports the notion that this group repre-
sents a distinct biological subgroup. Methylation profiles of bio-
logical subgroups associated with tumor location have also
been reported in other tumor entities such as ependymal tu-
mors8 and glioblastoma.10 Of note, copy-number alterations
encountered in the adult patients of methylation cluster 2
were well in line with previous observations in older choroid
plexus tumor patients.5,15 A recent retrospective series suggest-
ed that choroid plexus tumors in adults might be associated
with less favorable outcome.16 In the present study, however,
adult choroid plexus tumors of methylation cluster 2 did not
show worse outcome as compared with the pediatric choroid
plexus tumors of methylation cluster 1.
In conclusion, methylation profiling reveals 3 clinically dis-
tinct molecular subgroups of choroid plexus tumors: pediatric
low-risk choroid plexus tumors (cluster 1), adult low-risk cho-
roid plexus tumors (cluster 2), and pediatric high-risk choroid
plexus tumors (cluster 3). Because aCPPs clustering within clus-
ter 3 show an increased risk of progression as compared with
aCPPs of clusters 1 and 2, methylation profiling may provide
useful prognostic information in addition to histopathology in
the diagnosis of choroid plexus tumors.
Supplementary Material
Supplementary material is available at Neuro-Oncology Journal
online (http://neuro-oncology.oxfordjournals.org/).
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